DV
Dividend Vision

ADXN — Addex Therapeutics Ltd

Addex Therapeutics Ltd (ADXN)

Total return is -97.9% over the past 6.5 years, 258.7 points behind SPY at 160.8%. Its deepest 1-year drawdown was 52.5%.

Addex Therapeutics Ltd is a Swiss biopharmaceutical company that discovers and develops small-molecule drugs targeting G-protein coupled receptors and enzymes for neurological disorders. Its pipeline includes Dipraglurant in phase 1 trials for post-stroke recovery and Parkinson's disease, along with other programs in development through partnerships with Janssen Pharmaceuticals and Indivior. The company does not currently distribute dividends.

ADXN key facts

Asset type
Stock
Asset class
Equity
Inception date
01/29/2020
Last close
$5.95
Market cap
$7,209,108
Average volume
104.0
Beta
1.994
Payout ratio
0.0
Forward P/E
0.0
EPS
$-8.90